
浏览全部资源
扫码关注微信
1.贵州医科大学 贵州省药物制剂重点实验室,省部共建药用植物功效与利用国家重点实验室, 贵阳 550004
2.贵州医科大学 药学院,贵阳 550004
3.贵州医科大学 民族药与中药开发应用教育部工程研究中心,贵阳 550004
曹陶涛,在读硕士,从事中药药理研究,E-mail:1810500300@qq.com
刘亭,博士,教授,从事中药药理研究,E-mail:liuting@gmc.edu.cn
收稿日期:2021-10-20,
网络出版日期:2021-11-30,
纸质出版日期:2022-02-05
移动端阅览
曹陶涛,杨畅,孙佳等.黑骨藤靶向TNF-α抗类风湿关节炎的药效物质基础分析[J].中国实验方剂学杂志,2022,28(03):187-195.
CAO Tao-tao,YANG Chang,SUN Jia,et al.Effective Components of Periploca forrestii Against Rheumatoid Arthritis by Targeting TNF-α[J].Chinese Journal of Experimental Traditional Medical Formulae,2022,28(03):187-195.
曹陶涛,杨畅,孙佳等.黑骨藤靶向TNF-α抗类风湿关节炎的药效物质基础分析[J].中国实验方剂学杂志,2022,28(03):187-195. DOI: 10.13422/j.cnki.syfjx.20220211.
CAO Tao-tao,YANG Chang,SUN Jia,et al.Effective Components of Periploca forrestii Against Rheumatoid Arthritis by Targeting TNF-α[J].Chinese Journal of Experimental Traditional Medical Formulae,2022,28(03):187-195. DOI: 10.13422/j.cnki.syfjx.20220211.
目的
2
应用网络药理学和实验验证,分析黑骨藤靶向肿瘤坏死因子-
α
(TNF-
α
)治疗类风湿关节炎的药效物质基础。
方法
2
课题组前期研究发现黑骨藤醇提组分(CDLF,CQAF)具有显著抗类风湿关节炎(RA)活性,并鉴定出10个具有抗RA的活性单体。应用酶联免疫吸附测定法(ELISA),以白细胞介素-6(IL-6),一氧化氮(NO),白细胞介素-1
β
(IL-1
β
)和前列腺素E
2
(PGE
2
)为指标比较活性单体,CDLF和CQAF组分抗RA活性;网络药理学分析黑骨藤抗RA可能的分子机制;TNF-
α
分子对接、表面等离子分子互作(SPR)技术和TNF-
α
诱导L929损伤模型验证黑骨藤化学单体靶向TNF-
α
能力。
结果
2
ELISA发现,CDLF和CQAF组分抗RA活性明显高于鉴定出的10个活性单体;网络药理学分析,发现黑骨藤抗RA的核心靶点为信号传导及转录因子3(STAT3),肿瘤坏死因子(TNF)和IL-6,基因本体(GO)富集有胶原分解代谢、炎症反应,核转录因子(NF)-
κ
B转录因子活性的正调控,B细胞增殖的正调控等,基于京都基因与基因组百科全书(EKGG)富集有TNF信号通路,磷脂酰肌醇3-激酶(PI3K)/蛋白激酶B(Akt)信号通路,NF-
κ
B信号通路,Toll样受体信号通路,丝裂原活化蛋白激酶(MAPK)信号通路等;TNF-
α
分子对接,SPR技术和TNF-
α
诱导L929损伤模型实验发现,CDLF和CQAF组分具有较好的结合并拮抗TNF-
α
的活性,但从两组分中分离鉴定的活性成分,并没有表现出与CDLF和CQAF组分一致的抗TNF-
α
活性。
结论
2
黑骨藤的CDLF和CQAF组分可能通过靶向TNF-
α
治疗RA,实验发现已分离的化学成分与TNF-
α
结合活性低于CDLF和CQAF组分,同时课题组在黑骨藤药材中分离到最低质量分数为0.25 ng·g
-1
的化学成分,说明与TNF-
α
结合而产生抗RA活性成分可能为痕量成分。
Objective
2
To analyze the effective components of
Periploca forrestii
against
rheumatoid arthritis(RA)by targeting tumor necrosis factor (TNF)-
α
based on network pharmacology and experimental verification.
Method
2
The preliminary research of the research group found that the alcohol extracts of
P. forrestii
(CDLF and CQAF) had significant anti-RA activities,and 10 monomers with such activities were identified. The anti-RA activities of active monomers,CDLF, and CQAF were compared by the enzyme-linked immunosorbent assay (ELISA)with interleukin(IL)-6,nitric oxide (NO),IL-1
β
, and prostaglandin E
2
(PGE
2
)as indicators. Network pharmacology was employed to analyze the possible molecular mechanism of
P. forrestii
against RA. The targeting ability of
P. forrestii
chemical monomers to TNF-
α
was verified by TNF-
α
molecular docking,surface plasmon resonance (SPR), and TNF-
α
-induced L929 injury model.
Result
2
ELISA showed that the anti-RA activities of CDLF and CQAF were significantly stronger than those of identified 10 active monomers. Network pharmacology analysis showed that the core targets of
P. forrestii
against RA were signal transducer and activator of transcription protein 3 (STAT3),TNF, and IL-6. Gene Ontology(GO) analysis revealed collagen catabolism,inflammatory response,positive regulation of nuclear factor kappa-B(NF-
κ
B) transcription factor activity,and positive regulation of B cell proliferation. Kyoto Encyclopedia of Genes and Genomes (EKGG) pathway enrichment analysis demonstrated TNF signaling pathway,phosphoinositide 3-kinase(PI3K)/protein kinase B(Akt) signaling pathway,NF-
κ
B signaling pathway,Toll-like receptor signaling pathway,mitogen-activated protein kinase(MAPK) signaling pathway, etc. Verification experiments by TNF-α molecular docking,SPR, and TNF-
α
-induced L929 injury model found that CDLF and CQAF had good binding activities and could manifestly antagonize TNF-
α
. However, the active components separated and identified from CDLF and CQAF did not show the same anti-TNF-
α
activity.
Conclusion
2
The CDLF and CQAF of
P. forrestii
may treat RA by targeting TNF-
α
. The experiments found that the isolated chemical components had weaker binding activity to TNF-
α
than CDLF and CQAF. Meanwhile,the research group isolated chemical components with a minimum mass fraction of 0.25 ng·g
-1
from
P. forrestii
, which suggested that the active components generated by binding to TNF-
α
with anti-RA activities were presumedly trace components .
SPARKS J A . Rheumatoid arthritis [J]. Ann Intern Med , 2019 , 170 ( 1 ): ITC1 - ITC16 .
中华医学会风湿病学分会 . 2018中国类风湿关节炎诊疗指南 [J]. 中华内科杂志 , 2018 , 57 ( 4 ): 242 - 251 .
张锟 , 刘源 , 郭艳幸 . 中医药治疗类风湿关节炎研究进展 [J]. 风湿病与关节炎 , 2015 , 4 ( 12 ): 77 - 80 .
BURMESTER G R , POPE J E . Novel treatment strategies in rheumatoid arthritis [J]. Lancet , 2017 , 389 ( 10086 ): 2338 - 2348 .
王静 , 赵庆杰 , 卓小斌 , 等 . 类风湿性关节炎的治疗药物研究进展 [J]. 药学实践杂志 , 2019 , 37 ( 6 ): 485 - 490 .
池里群 , 周彬 , 高文远 , 等 . 治疗类风湿性关节炎常用药物的研究进展 [J]. 中国中药杂志 , 2014 , 39 ( 15 ): 2851 - 2858 .
ZHANG Q , LIU J , ZHANG M , et al . Apoptosis Induction of fibroblast-like synoviocytes is an important molecular-mechanism for herbal medicine along with its active components in treating rheumatoid arthritis [J]. Biomolecules , 2019 , 9 ( 12 ): 795 .
杨波 , 张建锋 . 苗药黑骨藤研究进展 [J]. 中国现代中药 , 2019 , 21 ( 8 ): 1122 - 1126 .
贵州省药品监督管理局 . 贵州省中药材、民族药材质量标准 [M]. 贵阳 : 贵州科学技术出版社 , 2003 : 381 .
李雪峰 , 刘育辰 , 刘刚 , 等 . 苗药黑骨藤化学成分及药理作用研究进展 [J]. 中成药 , 2018 , 40 ( 4 ): 904 - 912 .
燕晓婷 , 陈华国 , 周欣 . 苗药黑骨藤研究进展 [J]. 中国药学杂志 , 2019 , 54 ( 4 ): 259 - 263 .
CHEN L , LI J , KE X , et al . The therapeutic effects of Periploca forrestii Schltr. Stem extracts on collagen-induced arthritis by inhibiting the activation of Src/NF- κ B signaling pathway in rats [J]. J Ethnopharmacol , 2017 , 202 : 12 - 19 .
LI J , CHEN L , XU J , et al . Effects of Periploca forrestii Schltr on wound healing by Src meditated Mek/Erk and PI3K/Akt signals [J]. J Ethnopharmacol , 2019 , 237 : 116 - 127 .
LIU T , WANG X , HE Y L , et al . In vivo and In vitro anti-arthritic effects of cardenolide-rich and caffeoylquinic acid-rich fractions of Periploca forrestii [J]. Molecules , 2018 , 23 ( 8 ): 1988 .
LUO T T , LU Y , YAN S K , et al . Network pharmacology in research of chinese medicine formula: methodology,application and prospective [J]. Chin J Integr Med , 2020 , 26 ( 1 ): 72 - 80 .
李梢 . 网络药理学评价方法指南 [J]. 世界中医药 , 2021 , 16 ( 4 ): 527 - 532 .
李泮霖 , 苏薇薇 . 网络药理学在中药研究中的最新应用进展 [J]. 中草药 , 2016 , 47 ( 16 ): 2938 - 2942 .
SUN W , WU Y , ZHENG M , et al . Discovery of an orally active small-molecule tumor necrosis factor-α inhibitor [J]. J Med Chem , 2020 , 63 ( 15 ): 8146 - 8156 .
PAPANEOPHYTOU C P , METTOU A K , RINOTAS V , et al . Solvent selection for insoluble ligands,a challenge for biological assay development: A TNF- α /SPD304 study [J]. ACS Med Chem Lett , 2012 , 4 ( 1 ): 137 - 141 .
CHEN Z , BOZEC A , RAMMING A , et al . Anti-inflammatory and immune-regulatory cytokines in rheumatoid arthritis [J]. Nat Rev Rheumatol , 2019 , 15 ( 1 ): 9 - 17 .
FELDMANN M , MAINI R N . Discovery of TNF-alpha as a therapeutic target in rheumatoid arthritis:preclinical and clinical studies [J]. Joint Bone Spine , 2002 , 69 ( 1 ): 12 - 18 .
STRAND V , GREENBERG J D , GRIFFITH J , et al . Impact of treatment with biologic agents on the use of mechanical devices among rheumatoid arthritis patients in a large US patient registry [J]. Arthritis Care Res (Hoboken) , 2016 , 68 ( 7 ): 914 - 921 .
王霞 , 杨健 , 宋菲 , 等 . 苗药黑骨藤中咖啡酰基奎宁酸类部位对人类风湿性关节炎成纤维样滑膜细胞MH7A增殖及炎症因子分泌的影响 [J]. 中国药房 , 2017 , 28 ( 28 ): 3949 - 3952 .
王霞 , 蒋礼 , 何燕玲 , 等 . 黑骨藤中咖啡酰基奎宁酸类化合物体外抗类风湿性关节炎机制研究 [J]. 中国药理学通报 , 2018 , 34 ( 10 ): 1362 - 1367 .
李亚芹 , 闫勇 , 黄敏 , 等 . 类风湿性关节炎患者血清GM-CSF,IL-6,TNF- α 水平的变化及其临床意义 [J]. 现代生物医学进展 , 2017 , 17 ( 24 ): 4702 - 4705 .
TAKAHASHI S , INOUE T , HIGAKI M , et al . Suppressive effects of the new antirheumatic drug KE-298 on TNF alpha-induced production of matrix metalloproteinases but not of tissue inhibitor-1 of metalloproteinases in human rheumatoid synoviocytes [J]. Drugs Exp Clin Res , 1998 , 24 ( 2 ): 67 - 71 .
LI J , TANG R S , SHI Z , et al . Nuclear factor- κ B in rheumatoid arthritis [J]. Int J Rheum Dis , 2020 , 23 ( 12 ): 1627 - 1635 .
王泽 , 高玉亭 , 李振 , 等 . 二妙散对CIA大鼠关节NF- κ B p50和ERK1/2表达特性的影响 [J]. 中国免疫学杂志 , 2020 , 36 ( 16 ): 1951 - 1956 .
张行 , 保国锋 , 崔志明 . PI3K/AKT信号通路在类风湿关节炎发病机制中的研究进展 [J]. 东南大学学报:医学版 , 2019 , 38 ( 2 ): 358 - 363 .
周凡琦 , 冷静 , 运晨霞 . Toll样受体与类风湿性关节炎的相关性及靶向防治的研究进展 [J]. 广西医学 , 2020 , 42 ( 11 ): 1430 - 1434 .
SCHERER H U , HÄUPL T , BURMESTER G R . The etiology of rheumatoid arthritis [J]. J Autoimmun , 2020 , 110 : 102400 .
黄璟 , 周毅 . 肿瘤坏死因子 α 及其抑制剂的研究进展 [J]. 国际口腔医学杂志 , 2015 , 42 ( 1 ): 63 - 68 .
冯馨锐 , 崔雨舒 , 何志涛 , 等 . 肿瘤坏死因子-α的生物学功能研究进展 [J]. 吉林医药学院学报 , 2019 , 40 ( 1 ): 66 - 68 .
ABRAMSON S B , YAZICI Y . Biologics in development for rheumatoid arthritis: relevance to osteoarthritis [J]. Adv Drug Deliv Rev , 2006 , 58 ( 2 ): 212 - 225 .
厉彦山 , 姜林娣 . 肿瘤坏死因子及其受体在类风湿关节炎中的作用 [J]. 复旦学报:医学版 , 2010 , 37 ( 2 ): 245 - 249 .
赵珊 , 张宝 , 熊丹丹 , 等 . 苗药黑骨藤的化学成分研究 [J]. 中草药 , 2017 , 48 ( 8 ): 1513 - 1518 .
0
浏览量
17
下载量
2
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621